WO2003034984A9 - Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders - Google Patents

Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders Download PDF

Info

Publication number
WO2003034984A9
WO2003034984A9 PCT/US2002/033070 US0233070W WO03034984A9 WO 2003034984 A9 WO2003034984 A9 WO 2003034984A9 US 0233070 W US0233070 W US 0233070W WO 03034984 A9 WO03034984 A9 WO 03034984A9
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
compositions
treatment
methods
inflammatory bowel
Prior art date
Application number
PCT/US2002/033070
Other languages
French (fr)
Other versions
WO2003034984A2 (en
Inventor
Audrey Goddard
Austin L. Gurney
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US34008301P priority Critical
Priority to US60/340,083 priority
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of WO2003034984A2 publication Critical patent/WO2003034984A2/en
Publication of WO2003034984A9 publication Critical patent/WO2003034984A9/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1018Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
    • A61K51/1003Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
    • A61K51/1027Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups against receptors, cell-surface antigens, cell-surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
PCT/US2002/033070 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders WO2003034984A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US34008301P true 2001-10-19 2001-10-19
US60/340,083 2001-10-19

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US10/491,997 US20050089957A1 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
CA002461665A CA2461665A1 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2002351505A AU2002351505B2 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
JP2003537553A JP2005522986A (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disease
EP02786421A EP1578385A4 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
AU2008202957A AU2008202957B2 (en) 2001-10-19 2008-07-03 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US12/454,362 US20090311261A1 (en) 2001-10-19 2009-05-14 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US12/454,360 US20090311260A1 (en) 2001-10-19 2009-05-14 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US14/071,257 US20140193332A1 (en) 2001-10-19 2013-11-04 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/491,997 A-371-Of-International US20050089957A1 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US12/454,362 Continuation US20090311261A1 (en) 2001-10-19 2009-05-14 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US12/454,360 Continuation US20090311260A1 (en) 2001-10-19 2009-05-14 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders

Publications (2)

Publication Number Publication Date
WO2003034984A2 WO2003034984A2 (en) 2003-05-01
WO2003034984A9 true WO2003034984A9 (en) 2011-01-20

Family

ID=23331789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/033070 WO2003034984A2 (en) 2001-10-19 2002-10-15 Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders

Country Status (6)

Country Link
US (4) US20050089957A1 (en)
EP (1) EP1578385A4 (en)
JP (5) JP2005522986A (en)
AU (2) AU2002351505B2 (en)
CA (3) CA2842429A1 (en)
WO (1) WO2003034984A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070936A1 (en) * 2002-02-20 2003-08-28 Yamanouchi Pharmaceutical Co., Ltd. Novel polypeptide
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JP2007530588A (en) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド Receptor coupling agent and its therapeutic applications
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (en) 2004-06-09 2006-07-26 Wyeth Corp Antibodies against human interleukin-13 and uses thereof
SI1791565T1 (en) 2004-09-23 2016-08-31 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
EP1846443A4 (en) * 2005-01-07 2008-07-23 Glaxo Group Ltd Novel use
PT2314623E (en) 2005-06-21 2012-10-02 Xoma Technology Ltd Il-1beta binding antibodies and fragments thereof
PL2532679T3 (en) 2005-10-21 2017-09-29 Novartis Ag Human antibodies against il13 and therapeutic uses
AU2007351514B2 (en) * 2006-09-08 2013-02-21 Abbvie Inc. Interleukin -13 binding proteins
RU2554747C9 (en) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Method of treating il-1beta-dependent diseases
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
WO2009146207A1 (en) * 2008-04-17 2009-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Cripto-1 as a biomarker for chronic inflammatory disease
CN102171365B (en) * 2008-08-25 2014-01-29 森托科尔奥索生物科技公司 Biomarkers for anti-TNF treatment in ulcerative colitis and related disorders
CA2735939A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
EP2352508B1 (en) 2008-10-17 2014-04-02 Dana-Farber Cancer Institute, Inc. Muc-1 cytoplasmic domain peptides as inhibitors of cancer
KR20190069615A (en) 2008-12-09 2019-06-19 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2379102A1 (en) * 2008-12-30 2011-10-26 Syddansk Universitet Fibcd1 for the prevention and treatment of diseases
CN102665748A (en) * 2009-05-27 2012-09-12 属肿瘤有限责任公司 Inhibition 0f inflammation using antagonists of MUC1
WO2011031870A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
WO2011100688A1 (en) 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
AU2011239507B2 (en) 2010-04-15 2015-04-09 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN102883748A (en) 2010-05-07 2013-01-16 爱克索马技术有限公司 Methods for the treatment of IL-1beta related conditions
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
ES2544608T3 (en) 2010-11-17 2015-09-02 Genentech, Inc. Conjugates of the antibody and alaninyl-maytansinol
RU2638806C2 (en) 2011-05-12 2017-12-15 Дженентек, Инк. Lc-ms/ms method for multiple reactions monitoring to identify therapeutic antibodies in animal species using framework signature peptides
JP6320300B2 (en) 2011-12-19 2018-05-09 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー Methods for the treatment of acne
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
HUE035694T2 (en) 2012-10-12 2018-05-28 Adc Therapeutics Sa Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and their complexes
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CN105050661B (en) 2012-10-12 2018-03-30 Adc疗法责任有限公司 Pyrrolo benzodiazepine - antibody conjugate
JP6307519B2 (en) 2012-12-21 2018-04-04 メドイミューン・リミテッドMedImmune Limited Pyrrolo benzodiazepines and its conjugate
JP6527466B2 (en) 2012-12-21 2019-06-05 メドイミューン・リミテッドMedImmune Limited Asymmetric pyrrolobenzodiazepine dimers for use in the treatment of proliferative and autoimmune diseases
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
NZ710746A (en) 2013-03-13 2018-11-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
BR112015023140A8 (en) 2013-03-15 2018-01-23 Genentech Inc fusion proteins, the method for manufacturing the fusion protein, compositions, nucleic acid, vector, host cell, methods of producing a fusion protein treatment of inflammatory bowel disease, inhibition of microbial infection, treatment of renal injury to accelerate or improve healing, for the prevention or treatment of a cardiovascular condition, for the treatment of metabolic syndrome and for the treatment of endotoxemia.
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
WO2015095212A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
CA2918139A1 (en) 2013-08-12 2015-02-19 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
WO2015052532A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3094973A1 (en) 2013-11-07 2016-11-23 Diagnodus Limited Biomarkers
MX2016007825A (en) 2013-12-16 2016-09-07 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof.
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc antibody and conjugated drug, compound, method of treatment and pharmaceutical composition
AU2015246037B2 (en) 2014-04-11 2018-04-12 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017531620A (en) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド Cysteine ​​engineered antibodies and conjugates
BR112017005393A2 (en) 2014-09-17 2017-12-05 Genentech Inc compound of formula I, the method of preparation of a conjugate of formula, formula A1 conjugate, composition comprising a mixture of antibody-drug conjugate compounds, pharmaceutical composition and use of a conjugate or a composition
AU2015358532A1 (en) 2014-12-03 2017-06-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
US10058613B2 (en) 2015-10-02 2018-08-28 Genentech, Inc. Pyrrolobenzodiazepine antibody drug conjugates and methods of use
EP3362100A1 (en) 2015-10-16 2018-08-22 Genentech, Inc. Hindered disulfide drug conjugates
WO2017068511A1 (en) 2015-10-20 2017-04-27 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
CN108700598A (en) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 Multiplexed total antibody and antibody-conjugated drug quantification assay
EP3458101A1 (en) 2016-05-20 2019-03-27 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
EP3465221A1 (en) 2016-05-27 2019-04-10 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
US20170348422A1 (en) 2016-06-06 2017-12-07 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2018035615A1 (en) * 2016-08-26 2018-03-01 Thrasos Therapeutics Inc. Compositions and methods for the treatment of inflammatory bowel diseases
WO2018065501A1 (en) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Methods for preparing antibody drug conjugates
WO2019060398A1 (en) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Thailanstatin analogs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0527283B1 (en) * 1991-08-12 1997-11-26 Societe Des Produits Nestle S.A. Food composition
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
EP0839196B1 (en) * 1995-07-19 2005-05-11 Genetics Institute, LLC Human ctla-8 and uses of ctla-8-related proteins
US5872234A (en) * 1997-06-27 1999-02-16 Incyte Pharmaceuticals, Inc. Human extracellular matrix proteins
AU9395998A (en) * 1997-09-17 1999-04-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
CA2303834A1 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003524600A (en) * 1998-09-17 2003-08-19 ジェネンテック・インコーポレーテッド Compositions and methods for immune-related diseases
AU768507B2 (en) * 1998-03-03 2003-12-11 Genaera Corporation Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
US6228585B1 (en) * 1998-09-04 2001-05-08 Washington University Gene markers for chronic mucosal injury
PT1897944E (en) * 1999-12-23 2011-11-28 Genentech Inc Il-17 homologous polypeptides and therapeutic uses thereof
PT1210428E (en) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, a receptor for b7-4, and uses therefor
CA2356207C (en) * 1999-10-21 2012-10-09 Case Western Reserve University Gene expression profiling of inflammatory bowel disease
CA2389722A1 (en) * 1999-11-09 2001-05-17 Human Genome Sciences, Inc. 15 human secreted proteins
US20040224306A1 (en) * 1999-11-30 2004-11-11 Frederich-Wilhelm Kuhne Evaluating and predicting clinical outcomes by gene expression analysis
US6635750B1 (en) * 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family

Also Published As

Publication number Publication date
AU2008202957A1 (en) 2008-07-31
US20140193332A1 (en) 2014-07-10
US20090311260A1 (en) 2009-12-17
AU2008202957B2 (en) 2012-05-31
WO2003034984A2 (en) 2003-05-01
EP1578385A4 (en) 2011-11-09
AU2002351505B2 (en) 2008-04-03
EP1578385A2 (en) 2005-09-28
JP2005522986A (en) 2005-08-04
US20090311261A1 (en) 2009-12-17
CA2842429A1 (en) 2003-05-01
CA2461665A1 (en) 2003-05-01
JP2009159948A (en) 2009-07-23
CA2675409A1 (en) 2003-05-01
JP2013172712A (en) 2013-09-05
US20050089957A1 (en) 2005-04-28
JP2009159949A (en) 2009-07-23
JP2013140167A (en) 2013-07-18

Similar Documents

Publication Publication Date Title
AUPR638101A0 (en) Composition and method for treatment of disease
IL159344D0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2002303956A1 (en) U5-200kds as modifiers of the p53 pathway and methods of use
AU2002320264A1 (en) GFATs as modifiers of the p53 pathway and methods of use
AU2002310256A1 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
EP1576150A3 (en) Methods and compositions for increasing the efficacy of biologically-active ingredients
AU2003205737A1 (en) Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies
SI2092935T1 (en) Pharmaceutical compositions for the treatment of asthma
WO2001078781A8 (en) Methods for prevention and treatment of gastrointestinal disorders
AU2001257146A1 (en) Methods for prevention and treatment of gastrointestinal disorders
SI1594517T1 (en) Compositions for the treatment of gastrointestinal disorders
EP1628530B8 (en) Methods and compositions for the prevention and treatment of sepsis
AU2001261474A1 (en) Compositions and methods for the treatment of cancer
AU6825901A (en) Compositions and methods for the therapy and diagnosis of colon cancer
AU2002352726A8 (en) Formulations and methods for treatment or amelioration of inflammatory conditions
IL156784D0 (en) 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
EP1143956A3 (en) Compositions and methods for the treatment of anorectal disorders
AU2002239841A1 (en) Proteoglycan compositions for treatment of inflammatory conditions
AU6976601A (en) Compositions and methods for the therapy and diagnosis of colon cancer
PL199445B1 (en) Compositions for treatment of disorders of the oesophagus
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
EP1489915A4 (en) Treatment and prevention of inflammatory disorders
AU2002251841A1 (en) Compositions and methods for the therapy and diagnosis of pancreatic cancer
AU2001239826A1 (en) Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
AU2002239721A1 (en) Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002351505

Country of ref document: AU

Ref document number: 2461665

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10491997

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003537553

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2002786421

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002786421

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)